502 related articles for article (PubMed ID: 15287953)
1. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
2. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
3. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate.
Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M
Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685
[TBL] [Abstract][Full Text] [Related]
4. Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes.
Hiasa A; Nishikawa H; Hirayama M; Kitano S; Okamoto S; Chono H; Yu SS; Mineno J; Tanaka Y; Minato N; Kato I; Shiku H
Gene Ther; 2009 May; 16(5):620-8. PubMed ID: 19242528
[TBL] [Abstract][Full Text] [Related]
5. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
[TBL] [Abstract][Full Text] [Related]
6. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
7. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
8. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
9. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation.
Takahara M; Miyai M; Tomiyama M; Mutou M; Nicol AJ; Nieda M
J Leukoc Biol; 2008 Mar; 83(3):742-54. PubMed ID: 18156189
[TBL] [Abstract][Full Text] [Related]
10. Immune response of human propagated gammadelta-T-cells to neuroblastoma recommend the Vdelta1+ subset for gammadelta-T-cell-based immunotherapy.
Schilbach K; Frommer K; Meier S; Handgretinger R; Eyrich M
J Immunother; 2008; 31(9):896-905. PubMed ID: 18832998
[TBL] [Abstract][Full Text] [Related]
11. Perspectives of gammadelta T cells in tumor immunology.
Kabelitz D; Wesch D; He W
Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
13. Ex vivo characterization of γδ T-cell repertoire in patients after adoptive transfer of Vγ9Vδ2 T cells expressing the interleukin-2 receptor β-chain and the common γ-chain.
Izumi T; Kondo M; Takahashi T; Fujieda N; Kondo A; Tamura N; Murakawa T; Nakajima J; Matsushita H; Kakimi K
Cytotherapy; 2013 Apr; 15(4):481-91. PubMed ID: 23391461
[TBL] [Abstract][Full Text] [Related]
14. Innate anti-breast cancer immunity of apoptosis-resistant human gammadelta-T cells.
Guo BL; Liu Z; Aldrich WA; Lopez RD
Breast Cancer Res Treat; 2005 Sep; 93(2):169-75. PubMed ID: 16187237
[TBL] [Abstract][Full Text] [Related]
15. Human gammadelta T cells modulate the mite allergen-specific T-helper type 2-skewed immunity.
Korematsu S; Tanaka Y; Nagakura T; Minato N; Izumi T
Clin Exp Allergy; 2007 Nov; 37(11):1681-7. PubMed ID: 17883427
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes.
Pietschmann K; Beetz S; Welte S; Martens I; Gruen J; Oberg HH; Wesch D; Kabelitz D
Scand J Immunol; 2009 Sep; 70(3):245-55. PubMed ID: 19703014
[TBL] [Abstract][Full Text] [Related]
17. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
Birkholz K; Hombach A; Krug C; Reuter S; Kershaw M; Kämpgen E; Schuler G; Abken H; Schaft N; Dörrie J
Gene Ther; 2009 May; 16(5):596-604. PubMed ID: 19158846
[TBL] [Abstract][Full Text] [Related]
18. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.
Cheadle EJ; Gilham DE; Thistlethwaite FC; Radford JA; Hawkins RE
Br J Haematol; 2005 May; 129(3):322-32. PubMed ID: 15842655
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
[TBL] [Abstract][Full Text] [Related]
20. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]